Study Finds No Significant Difference in Dementia Risk Between GLP-1 RAs and DPP4 Inhibitors in Older Adults with Type 2 Diabetes
A recent study shows no significant difference in dementia risk among older adults with type 2 diabetes taking GLP-1 RAs or DPP4 inhibitors, highlighting the need for personalized treatment decisions.
Recent research published in the Annals of Internal Medicine indicates that for seniors with type 2 diabetes, the choice between glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) does not significantly influence the risk of developing dementia. The study analyzed data from Medicare beneficiaries aged 66 and older who were using metformin and initiating either GLP-1 RAs or DPP4is between January 2017 and December 2018.
A total of 2,418 patients starting on GLP-1 RAs were compared to 4,836 matched patients initiating DPP4is, with the average age around 71 years. Over a median follow-up period of nearly two years, 96 patients in the GLP-1 group and 217 in the DPP4i group developed dementia. The analysis showed that at 30 months, the risk difference was approximately -0.93%, and the risk ratio was around 0.83, suggesting no definitive benefit of one medication class over the other in reducing dementia risk.
Interestingly, when examining age subgroups, there was a hint that younger seniors (under 75) might experience a somewhat lower risk with GLP-1 RAs, with a risk ratio of 0.64. However, for those aged 75 and older, the risk appeared slightly higher, with a risk ratio of 1.22. Despite these observations, the overall evidence does not establish a causal relationship between the type of diabetes medication and dementia prevention.
This study provides valuable insights for clinicians managing older adults with diabetes, emphasizing that the selection of GLP-1 RAs or DPP4is should consider other factors beyond dementia risk. Further research is needed to clarify potential age-related effects and underlying mechanisms.
Source: https://medicalxpress.com/news/2025-07-dementia-differ-glp-ras-dpp4is.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhanced Technique Improves Precision of Blood Measurement Using Near-Infrared Spectroscopy
A new integrated approach significantly improves the accuracy of blood hemoglobin measurement using near-infrared spectroscopy, paving the way for non-invasive diagnostics.
Unveiling the Impact of Senescent Cells on Aging at the Single-Cell Level
New research reveals how senescent cells influence tissue aging and dysfunction through complex interactions uncovered at the single-cell level in vivo. These findings provide critical insights into the role of cellular senescence in aging and age-related diseases.
Study Highlights Differences Between Treadmill and Outdoor Running Using Wearable Technology
A recent study using wearable sensors reveals significant biomechanical differences between treadmill and outdoor running, offering insights into injury risk and prevention strategies.